Male Hypogonadism Treatment Algorithm by Line of Therapy

Step Zero: Confirming the Diagnosis

A correct diagnosis prevents years of unnecessary therapy. The 2018 Endocrine Society Clinical Practice Guideline requires two separate morning fasting total testosterone measurements below 300 ng/dL, combined with at least one specific sign or symptom: reduced libido, erectile dysfunction, decreased spontaneous erections, gynecomastia, loss of body hair, small testes, infertility, or low bone mineral density [1].

Blood should be drawn before 10:00 AM because testosterone follows a circadian rhythm, peaking between 06:00 and 08:00 and declining 20 to 25% by afternoon. Fasting matters too. A 2013 study in Clinical Endocrinology (N=3,006) showed that glucose ingestion acutely suppresses testosterone by approximately 25% for up to two hours [2]. The AUA 2018 guideline echoes this requirement and adds that free testosterone should be measured when total T is borderline (between 220 and 400 ng/dL) or when sex hormone-binding globulin (SHBG) abnormalities are suspected, such as in obesity or liver disease [3].

Once low testosterone is confirmed biochemically, the next step is classifying it. Primary hypogonadism (testicular failure) presents with high LH and FSH. Secondary hypogonadism (hypothalamic-pituitary dysfunction) shows low or inappropriately normal gonadotropins. This distinction matters because it determines both prognosis and treatment selection.

The 2018 AUA guideline from Mulhall et al. specifically recommends measuring LH, FSH, and prolactin in all men with confirmed low testosterone to identify treatable secondary causes, including prolactinomas, hemochromatosis, and exogenous opioid use [3].

First Line: Lifestyle Optimization and Reversible-Cause Correction

Before prescribing any medication, address what can be fixed without a prescription. The Endocrine Society classifies obesity-related testosterone suppression as "functional hypogonadism," a condition where the hypothalamic-pituitary-gonadal axis is suppressed by excess adipose tissue rather than by structural damage [1].

Weight loss produces measurable testosterone recovery. A meta-analysis published in JAMA Internal Medicine (2022, 28 RCTs, N=1,489) found that lifestyle interventions resulting in at least 5% body weight loss increased total testosterone by a mean of 2.93 nmol/L (approximately 84 ng/dL) in men with obesity [4]. That magnitude of increase can move a man from below threshold to above it.

Medication review is equally important. Opioids suppress GnRH pulsatility and can reduce testosterone by 50% or more. A 2010 cross-sectional study in The Journal of Clinical Endocrinology & Metabolism found that 74% of men receiving long-acting opioids had total testosterone below 250 ng/dL [5]. Glucocorticoids, 5-alpha reductase inhibitors, and spironolactone also warrant review. Obstructive sleep apnea should be treated with CPAP, which may partially restore nocturnal testosterone pulsatility.

If testosterone normalizes after these interventions, no further pharmacotherapy is needed. Recheck levels at 3 months.

Second Line: Fertility-Sparing Pharmacotherapy

Exogenous testosterone suppresses the HPG axis and halts spermatogenesis. For men who want to preserve fertility (or who have not completed family planning), alternative agents that stimulate endogenous production are preferred.

Clomiphene citrate (25 to 50 mg every other day or daily, off-label) blocks estrogen receptors at the hypothalamus and pituitary, increasing GnRH pulse frequency and downstream LH/FSH secretion. A 2015 retrospective cohort published in BJU International (N=400) reported that clomiphene raised mean total testosterone from 228 ng/dL to 612 ng/dL at 3 months, with maintenance of sperm parameters [6].

Human chorionic gonadotropin (hCG) acts as an LH analog, directly stimulating Leydig cell testosterone production while preserving intratesticular testosterone concentrations needed for spermatogenesis. The typical dose is 1,500 to 3 to 000 IU subcutaneously two to three times per week. A 2019 study in The Journal of Urology found that hCG monotherapy maintained semen parameters while increasing serum testosterone by a mean of 150 ng/dL from baseline in hypogonadal men [7].

Enclomiphene, the trans-isomer of clomiphene, is under FDA review and may offer a cleaner pharmacologic profile with fewer estrogenic side effects than racemic clomiphene. The Phase 3 ZA-304 trial (N=258) showed that enclomiphene 12.5 mg and 25 mg daily both raised total testosterone above 450 ng/dL while maintaining sperm counts above 10 million/mL [8].

The AUA 2018 guideline does not formally endorse a specific fertility-sparing agent but acknowledges that "alternative therapies to raise endogenous testosterone while maintaining fertility should be discussed" with men of reproductive age [3]. This line of therapy is appropriate for secondary hypogonadism. It is unlikely to work in primary hypogonadism (testicular failure), where the testes cannot respond to increased gonadotropin signaling.

Third Line: Testosterone Replacement Therapy

When lifestyle measures fail, fertility is not a concern (or has been addressed), and the patient has confirmed organic hypogonadism, TRT becomes the standard of care. The Endocrine Society 2018 guideline recommends TRT for men with "consistently low serum testosterone concentrations and symptoms and signs associated with testosterone deficiency" [1].

Formulation Options

The choice of formulation depends on patient preference, insurance coverage, pharmacokinetic profile, and risk tolerance.

Topical gels (testosterone 1% or 1.62%) are the most commonly prescribed formulation in the United States. Applied daily to the shoulders or upper arms, they produce relatively steady-state levels within 2 to 4 weeks. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials (N=790 men aged 65 and older with T <275 ng/dL), used 1% gel and demonstrated improvements in sexual function, walking distance, and mood at 12 months [9]. Transference risk to household contacts (especially women and children) requires counseling.

Intramuscular injections of testosterone cypionate or enanthate (100 to 200 mg every 1 to 2 weeks, or 50 to 100 mg weekly for more stable levels) remain the least expensive option. Peak-trough fluctuations are their primary drawback, producing supraphysiologic peaks 48 to 72 hours post-injection and hypogonadal troughs before the next dose.

Testosterone undecanoate (Aveed) provides a long-acting intramuscular option (750 mg every 10 weeks after a loading period), but it carries an FDA-mandated REMS due to reports of pulmonary oil microembolism and anaphylaxis. Each injection must be administered in a healthcare setting with a 30-minute observation period [10].

Nasal testosterone (Natesto, 5.5 mg per nostril three times daily) avoids transference risk and produces a pulsatile pharmacokinetic profile that may partially preserve gonadotropin secretion. A 2016 Phase 3 trial (N=306) showed that nasal testosterone achieved target testosterone levels in 90% of men at 90 days, with an acceptable nasal tolerability profile [11].

Subcutaneous pellets (Testopel, 150 to 450 mg implanted every 3 to 6 months) provide the longest dosing interval among available formulations but require a minor office procedure and carry a 5 to 10% extrusion rate.

Absolute Contraindications to TRT

The Endocrine Society and AUA agree on the following absolute contraindications: desire for fertility in the near term, breast or prostate cancer (active or suspected), hematocrit above 50% at baseline, untreated severe obstructive sleep apnea, uncontrolled heart failure (NYHA Class III or IV), and unevaluated prostate nodules or PSA above 4 ng/mL (or above 3 ng/mL in high-risk men) [1][3].

Monitoring on Testosterone Therapy

Monitoring determines whether TRT is working and whether it is safe to continue. The Endocrine Society recommends checking total testosterone 3 to 6 months after initiation, then annually [1]. The goal is a mid-normal range (450 to 600 ng/dL).

Hematocrit is the most clinically significant safety parameter. Testosterone stimulates erythropoiesis through EPO-independent and EPO-dependent pathways. The TRAVERSE trial (N=5,246, mean age 63, mean follow-up 33 months), the largest cardiovascular safety trial of TRT to date, found that testosterone gel did not increase the incidence of major adverse cardiovascular events compared to placebo (HR 0.96 to 95% CI 0.78 to 1.17), but polycythemia (hematocrit above 54%) occurred in 4.7% of the testosterone group versus 1.1% of placebo [12]. If hematocrit exceeds 54%, the dose should be reduced, the formulation changed, or therapeutic phlebotomy initiated.

PSA should be measured at baseline, 3 to 6 months, 12 months, and annually thereafter. A confirmed PSA rise greater than 1.4 ng/mL within 12 months warrants urology referral [1]. Bone mineral density via DXA scan should be obtained after 1 to 2 years of TRT in men who had osteoporosis or severe testosterone deficiency at baseline.

Dr. Shalender Bhasin, principal investigator of the TTrials, has stated: "Testosterone treatment improved all aspects of sexual function, improved mood and depressive symptoms, and increased walking distance, but had no effect on vitality or cognitive function" [9]. This framing is important for patient counseling. TRT is not a panacea.

Fourth Line: Adjunctive and Combination Therapies

Some patients on TRT develop specific side effects or suboptimal responses that require add-on interventions.

Anastrozole (0.5 to 1 mg twice weekly) may be considered in men who develop symptomatic estradiol elevation (gynecomastia, nipple tenderness, water retention) on TRT. The Endocrine Society does not formally recommend routine aromatase inhibitor co-prescription, and a 2020 meta-analysis in Clinical Endocrinology cautioned that anastrozole use in hypogonadal men may adversely affect bone mineral density over time [13].

Low-dose hCG (500 IU subcutaneously every other day) is sometimes co-prescribed with TRT to maintain intratesticular testosterone and preserve some degree of spermatogenesis. This approach lacks large RCT evidence but is commonly used in reproductive urology practice.

GnRH pump therapy is reserved for secondary hypogonadism caused by hypothalamic pathology where fertility induction is desired and clomiphene has failed. Pulsatile GnRH (5 to 25 mcg every 90 to 120 minutes via subcutaneous pump) can restore both testosterone production and spermatogenesis in selected patients with congenital or acquired GnRH deficiency [14].

Special Populations: Obesity and Type 2 Diabetes

The overlap between male hypogonadism and metabolic disease is substantial. The TIMES2 trial (N=220, men with type 2 diabetes or metabolic syndrome and total T <300 ng/dL) showed that transdermal testosterone improved insulin resistance (HOMA-IR decreased by 15.2% vs. 5.4% with placebo) and reduced body fat by 2.4 kg at 6 months [15].

The ADA 2024 Standards of Care recommends measuring morning total testosterone in men with type 2 diabetes who present with symptoms of hypogonadism, particularly low libido and erectile dysfunction [16]. The recommendation stops short of screening all diabetic men, but the prevalence of biochemical hypogonadism in T2D cohorts ranges from 25 to 40% depending on the cutoff used and the population studied.

A practical decision point: if a man with T2D and a BMI above 35 has a total testosterone of 280 ng/dL, a weight loss intervention (lifestyle, GLP-1 receptor agonist, or bariatric surgery) may normalize testosterone without lifelong TRT. The JAMA Internal Medicine meta-analysis showed that bariatric surgery produced larger testosterone increases (mean +8.7 nmol/L) than diet and exercise alone [4].

When to Refer

Referral to endocrinology is warranted when LH and FSH are suppressed without an obvious cause (raising concern for pituitary tumor), when prolactin is elevated above 100 ng/mL, when testosterone is below 150 ng/dL with ambiguous classification, or when Klinefelter syndrome or other genetic causes are suspected. Urology referral is appropriate for fertility management, PSA abnormalities, or testicular pathology.

Men with hematocrit persistently above 54% despite dose adjustments should be evaluated by hematology to rule out concurrent polycythemia vera or other myeloproliferative disorders. Target trough testosterone for men on TRT is 400 to 600 ng/dL; levels persistently below 300 ng/dL despite adequate dosing suggest poor absorption (gel formulations), injection technique issues, or non-adherence.